[Federal Register: August 9, 2002 (Volume 67, Number 154)]
[Notices]
[Page 51862]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09au02-93]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Nonclinical Studies Subcommittee of the Advisory Committee for
Pharmaceutical Science; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Nonclinical Studies Subcommittee of the Advisory
Committee for Pharmaceutical Science.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 9, 2002, from
1 p.m. to 4:30 p.m. and September 10, 2002, from 8 a.m. to 12 noon.
Location: Center for Drug Evaluation and Research, Advisory
Committee conference room 1066, 5630 Fishers Lane, Rockville, MD.
Contact Person: Kathleen Reedy, Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857,
301-827-7001, e-mail: reedyk@cder.fda.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 12539. Please call the Information Line for up-to-date
information on this meeting.
Agenda: On September 9, 2002, the Chair of the expert working group
on cardiotoxicity will report on the progress and activities of the
group and the subcommittee will be allotted time to discuss the report.
The subcommittee will then discuss a plan to transfer oversight of the
subcommittee from the Advisory Committee for Pharmaceutical Science to
the Science Advisory Board of the National Center for Toxicological
Research. On September 10, 2002, the Chair of the expert working group
on vascular damage will report on the progress and activities of the
group and the subcommittee members will be allotted time to discuss the
report.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the subcommittee.
Written submissions may be made to the contact person by August 23,
2002. Oral presentations from the public will be scheduled between
approximately 10 a.m. and 11 a.m. on September 10, 2002. Time allotted
for each presentation may be limited. Those desiring to make formal
oral presentations should notify the contact person before August 23,
2002, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Carolyn Jones, 301-
827-7001, at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 2, 2002.
Linda Arey Skladany,
Senior Associate Commissioner for External Relations.
[FR Doc. 02-20162 Filed 8-8-02; 8:45 am]
BILLING CODE 4160-01-S